Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterized factors of subjects who were first time diagnosed as hyperglycemia more than 126 mg/dl during annual or biannual medical checkups: a case-control study in Japan.
Minami M, Imamura T, Takamori A, Minagawa H, Matsuo R, Miyakawa J, Izumi K, Ohta S, Yamanouchi K, Souta N, Yamamoto K, Tsuji S, Umemura T, Anzai K, Hirai Y, Fujimoto K, Kishi T. Minami M, et al. Among authors: miyakawa j. J Clin Biochem Nutr. 2024 Nov;75(3):217-221. doi: 10.3164/jcbn.24-98. Epub 2024 Aug 20. J Clin Biochem Nutr. 2024. PMID: 39583976 Free PMC article.
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Noda M, Kaneko T, Miyakawa J, Nakamura Y, Hoshina H, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Adachi Y, Sugimoto K, Sato K, Tabata M, Tanaka T, Nara K, Uemura Y, Kamei J, Akiyama Y, Sato Y, Yamada Y, Niimi A, Yamada D, Takada T, Takahashi S, Yamada Y, Miyazaki H, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Taguchi S, et al. Among authors: miyakawa j. Int J Urol. 2024 Nov 22. doi: 10.1111/iju.15640. Online ahead of print. Int J Urol. 2024. PMID: 39575880
Improvement trend for individual health guidance intervention according to Japan clinical guidelines by public health nurses for type 2 diabetes mellitus who visited for medical checkups regularly: a case-control preliminary report.
Matsuo R, Imamura T, Takamori A, Kishi T, Minami M, Miyakawa J, Yoshitake N, Hayashi A, Nakayama Y, Egashira N, Teramoto M, Ishinari H, Kajiyama I, Fujisaki S, Kakiyama H, Satou K, Nakafusa R, Tanaka C, Tanaka M, Isomura Y, Izumi K, Ohta S, Souta N, Matsuo N, Yamamoto K, Tsuji S, Umemura T, Takagi K, Fujimoto K. Matsuo R, et al. Among authors: miyakawa j. J Clin Biochem Nutr. 2024 Mar;74(2):141-145. doi: 10.3164/jcbn.23-52. Epub 2023 Aug 18. J Clin Biochem Nutr. 2024. PMID: 38510680 Free PMC article.
Th1/17 polarization and potential treatment by an anti-interferon-γ DNA aptamer in Hunner-type interstitial cystitis.
Akiyama Y, Harada K, Miyakawa J, Kreder KJ, O'Donnell MA, Daichi M, Katoh H, Hori M, Owari K, Futami K, Ishikawa S, Ushiku T, Kume H, Homma Y, Luo Y. Akiyama Y, et al. Among authors: miyakawa j. iScience. 2023 Oct 21;26(11):108262. doi: 10.1016/j.isci.2023.108262. eCollection 2023 Nov 17. iScience. 2023. PMID: 38026177 Free PMC article.
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, Nakamura Y, Noda M, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Taguchi S, et al. Among authors: miyakawa j. Int J Urol. 2023 Dec;30(12):1180-1186. doi: 10.1111/iju.15300. Epub 2023 Sep 22. Int J Urol. 2023. PMID: 37740409
Increasing age predicts adverse pathology including intraductal carcinoma of the prostate and cribriform patterns in deferred radical prostatectomy after upfront active surveillance for Gleason grade group 1 prostate cancer: analysis of prospective observational study cohort.
Tohi Y, Ishikawa R, Kato T, Miyakawa J, Matsumoto R, Mori K, Mitsuzuka K, Inokuchi J, Matsumura M, Shiga K, Naito H, Kohjimoto Y, Kawamura N, Inoue M, Akamatsu S, Terada N, Miyazawa Y, Narita S, Haba R, Sugimoto M. Tohi Y, et al. Among authors: miyakawa j. Jpn J Clin Oncol. 2023 Oct 4;53(10):984-990. doi: 10.1093/jjco/hyad088. Jpn J Clin Oncol. 2023. PMID: 37496400
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, Kume H. Taguchi S, et al. Among authors: miyakawa j. Immunotherapy. 2023 Aug;15(11):827-837. doi: 10.2217/imt-2023-0028. Epub 2023 May 16. Immunotherapy. 2023. PMID: 37191002
60 results